Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application for naringin in preparation for medicine preventing and treating respiratory diseases due to PM2.5 particles

Inactive Publication Date: 2014-07-02
苏薇薇
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The orange red extract containing naringin, naringin and naringenin all have significant antitussive, antiasthma, expectorant and anti-inflammatory effects, but there is no report on naringin or natural plant extracts containing naringin The application of drugs for the prevention and treatment of respiratory system damage caused by PM2.5

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application for naringin in preparation for medicine preventing and treating respiratory diseases due to PM2.5 particles
  • Application for naringin in preparation for medicine preventing and treating respiratory diseases due to PM2.5 particles
  • Application for naringin in preparation for medicine preventing and treating respiratory diseases due to PM2.5 particles

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1: Naringin inhibits cough, airway hyperresponsiveness and decreased lung function caused by PM2.5.

[0029] Take 132 Hartley guinea pigs, weighing 250-300g, and randomly divide them into a blank control group, a model group (all are given saline by intragastric administration), a naringin low-dose (8 weeks) group, a medium-dose (8 weeks) group, and a high-dose group. (8 weeks) group and medium-dose (2 weeks) group (intragastric administration of naringin at 9.2, 18.4, 36.8, 18.4 mg / kg body weight respectively), prednisone (8 weeks) group and prednisone (2 weeks) ) Group (all were given prednisone 2.4 mg / kg body weight by gavage), codeine phosphate (2 weeks) group (codeine phosphate 4.8 mg / kg body weight was given by gavage), mogistein (2 weeks) group (Mojisteine ​​24mg / kg body weight was given by gavage), levoxipropiperazine (2 weeks) group (levepiperazine 14mg / kg body weight was given by gavage), 12 rats in each group, half male and half.

[0030] After the guinea...

Embodiment 2

[0040] Example 2 The effect of naringin on mucus hypersecretion caused by PM2.5.

[0041] Take 132 Hartley guinea pigs, weighing 250-300g, and randomly divide them into a blank control group, a model group (all are given saline by intragastric administration), a naringin low-dose (8 weeks) group, a medium-dose (8 weeks) group, and a high-dose group. (8 weeks) group and medium dose (2 weeks) group (administer naringin by gavage at 9.2, 18.4, 36.8, 18.4 mg / kg body weight respectively), prednisone (8 weeks) group and prednisone (2 weeks) ) Group (all given prednisone 2.4 mg / kg body weight by gavage), codeine phosphate (2 weeks) group (gave codeine phosphate 4.8 mg / kg body weight), mogistein (2 weeks) group (Mojisteine ​​24mg / kg body weight was given by gavage), levoxipropiperazine (2 weeks) group (levepiperazine 14mg / kg body weight was given by gavage), 12 rats in each group, half male and half.

[0042] After the guinea pigs were adapted to rearing for 2 days, the model group and ea...

Embodiment 3

[0047] Example 3: Effect of Naringin on PM2.5-induced lung pro-inflammatory factors and enzymes

[0048] Take 132 Hartley guinea pigs, weighing 250-300g, and randomly divide them into a blank control group, a model group (all are given saline by intragastric administration), a naringin low-dose (8 weeks) group, a medium-dose (8 weeks) group, and a high-dose group. (8 weeks) group and medium dose (2 weeks) group (administer naringin by gavage at 9.2, 18.4, 36.8, 18.4 mg / kg body weight respectively), prednisone (8 weeks) group and prednisone (2 weeks) ) Group (all given prednisone 2.4 mg / kg body weight by gavage), codeine phosphate (2 weeks) group (gave codeine phosphate 4.8 mg / kg body weight), mogistein (2 weeks) group (Mojisteine ​​24mg / kg body weight was given by gavage), levoxipropiperazine (2 weeks) group (levepiperazine 14mg / kg body weight was given by gavage), 12 rats in each group, half male and half.

[0049] After the guinea pigs were adapted to rearing for 2 days, the mod...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application for a natural plant extract and monomers thereof in preparation for a medicine or a healthcare product preventing and treating respiratory injuries due to PM2.5 particles. The extract and the monomers thereof are a naringin-containing natural plant extract and the naringin monomers thereof. The application is exact in curative effect on the symptoms of cough, phlegm, asthma, airway inflammation and the like due to PM2.5 particles, high in safety, obviously superior to the single effect of clinically common cough-relieving medicines, phlegm-dispelling medicines, antiasthmatic medicines and anti-inflammatory medicines at present, and capable of solving the disease of the compound occurrence of various respiratory injury symptoms due to the pollution of PM2.5 particles.

Description

Technical field [0001] The invention discloses the application of naringin in preventing and treating respiratory system injury diseases caused by PM2.5 air pollution particles. Background technique [0002] PM2.5 refers to particulate matter with an aerodynamic particle size of less than or equal to 2.5 microns in the atmosphere, also known as lung particulate matter. Clinical studies have shown that particle size> 10 micron particles can be blocked outside the human nose. Although 2.5-10 micron particles can enter the upper respiratory tract, they can be blocked by nasal villi, or adhered by upper respiratory mucosa, forming sputum and excreted from the body. The health impact is relatively small. And the particle size Particles <2.5 microns are too small to be easily blocked by the inherent barriers of the respiratory system. Therefore, these small particles can directly enter the bronchi, bronchioles and even the alveoli after being inhaled. [0003] A large number of e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K36/752A61P11/00A61P29/00A61P11/06A61P11/14
Inventor 苏薇薇王永刚罗钰龙吴忠
Owner 苏薇薇
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com